Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Wenjian Min und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Jiangsu Planned Projects for Postdoctoral Research Funds, National Key Research and Development Program of China, State Key Laboratory of Natural Medicines.
Abstract (Originalsprache)
Targeting c-Met is a clinical trend for the precise treatment of HCC, but the potential issue of acquired drug resistance cannot be ignored. Targeted protein degradation technology has demonstrated promising prospects in disease treatment and overcoming drug resistance due to its special mechanism of action. In this study, we designed and synthesized two series of novel c-Met degraders and conducted a systematic biological evaluation of the optimal compound H11. H11 exhibited good c-Met degradation activity and anti-HCC activity. Importantly, H11 also demonstrated more potent inhibitory activity against Ba/F3-TPR-MET-D1228N and Ba/F3-TPR-MET-Y1230H cell lines than did tepotinib. In summary, H11 displayed potent anti-HCC activity as a degrader and may overcome resistance to type Ib inhibitors, making it a new therapeutic strategy for HCC with MET alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
Förderung
- Jiangsu Planned Projects for Postdoctoral Research Funds
- National Key Research and Development Program of China
- State Key Laboratory of Natural Medicines
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Min, W., Yang, H., Wang, D., Chen, C., Wang, Y., Hou, Y., Zhu, Y., Sun, C., Wang, X., Yuan, K., & Yang, P. (2024). Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01004
Vancouver
Min W, Yang H, Wang D, Chen C, Wang Y, Hou Y, et al. Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01004
BibTeX
@article{Min2024,
author = {Min, Wenjian and Yang, Huanaoyu and Wang, Dawei and Chen, Chunling and Wang, Yanyin and Hou, Yi and Zhu, Yasheng and Sun, Chengliang and Wang, Xiao and Yuan, Kai and Yang, Peng},
title = {Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01004}
}
EUVIMED